Suppr超能文献

对妊娠28至33周患有呼吸窘迫综合征的婴儿,采用无创神经调节通气辅助联合插管-表面活性剂-拔管技术的疗效和安全性评估。

The evaluation of the efficacy and safety of non-invasive neurally adjusted ventilatory assist in combination with INtubation-SURfactant-Extubation technique for infants at 28 to 33 weeks of gestation with respiratory distress syndrome.

作者信息

Miyahara Jun, Sugiura Hiroshi, Ohki Shigeru

机构信息

Department of Neonatology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

出版信息

SAGE Open Med. 2019 Mar 15;7:2050312119838417. doi: 10.1177/2050312119838417. eCollection 2019.

Abstract

OBJECTIVES

The aim of this study is to evaluate the efficacy and safety of non-invasive neurally adjusted ventilatory assist used after INtubation-SURfactant-Extubation in preterm infants with respiratory distress syndrome.

METHODS

We conducted a prospective observational study that included 15 inborn preterm infants at 28 (0/7) to 33 (6/7) weeks of gestation with respiratory distress syndrome in the period from April 2017 to October 2018. After INtubation-SURfactant-Extubation, infants underwent non-invasive neurally adjusted ventilatory assist. INtubation-SURfactant-Extubation failure was defined as follows: fraction of inspired oxygen requirement >0.4, respiratory acidosis, and severe apnea within 5 days after surfactant administration.

RESULTS

Two of the 15 (13.3%) infants showed INtubation-SURfactant-Extubation failure and required mechanical ventilation. No infants experienced any major complications such as pneumothorax, patent ductus arteriosus ligation, severe intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, or death.

CONCLUSION

The rate of INtubation-SURfactant-Extubation failure when non-invasive neurally adjusted ventilatory assist was used after INtubation-SURfactant-Extubation for preterm infants with respiratory distress syndrome was 13.3%. Non-invasive neurally adjusted ventilatory assist can be safely performed without severe complications for preterm infants soon after birth.

摘要

目的

本研究旨在评估在气管插管-使用表面活性剂-拔管后,对患有呼吸窘迫综合征的早产儿使用无创神经调节通气辅助的疗效和安全性。

方法

我们进行了一项前瞻性观察性研究,纳入了2017年4月至2018年10月期间15例胎龄28(0/7)至33(6/7)周、患有呼吸窘迫综合征的早产儿。在气管插管-使用表面活性剂-拔管后,对婴儿进行无创神经调节通气辅助。气管插管-使用表面活性剂-拔管失败的定义如下:在给予表面活性剂后5天内,吸入氧分数需求>0.4、呼吸性酸中毒和严重呼吸暂停。

结果

15例婴儿中有2例(13.3%)出现气管插管-使用表面活性剂-拔管失败,需要机械通气。没有婴儿发生任何重大并发症,如气胸、动脉导管未闭结扎、重度脑室内出血、脑室周围白质软化、早产儿视网膜病变或死亡。

结论

对于患有呼吸窘迫综合征的早产儿,在气管插管-使用表面活性剂-拔管后使用无创神经调节通气辅助时,气管插管-使用表面活性剂-拔管失败率为13.3%。出生后不久对早产儿安全实施无创神经调节通气辅助不会出现严重并发症。

相似文献

6

本文引用的文献

5
Non-invasive ventilation with neurally adjusted ventilatory assist in newborns.新生儿神经调节通气辅助的无创通气
Semin Fetal Neonatal Med. 2016 Jun;21(3):154-61. doi: 10.1016/j.siny.2016.01.006. Epub 2016 Feb 16.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验